EIF2AK3 and breast carcinoma: To provide further physiological evidence that FOXO3 regulates PERK and to investigate its potential relevance in breast cancer, FOXO3, PERK and P-eIF2α expression was assessed by immunohistochemical (IHC) staining in a HER2-positive cohort of breast cancer patient samples (Fig. 3a).